Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 11 (November)

1. Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer.
   Int J Cancer, 122(1): 209-18. [Abstract] [Full-text]
2. Methylseleninic acid inhibits microvascular endothelial G1 cell cycle progression and decreases tumor microvessel density.
   Int J Cancer, 122(1): 15-24. [Abstract] [Full-text]
3. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects.
   Int J Cancer, 122(1): 39-49. [Abstract] [Full-text]
4. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators.
   Int J Cancer, 122(1): 138-43. [Abstract] [Full-text]
5. Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells.
   J Biol Chem, 282(45): 32689-98. [Abstract] [Full-text]
6. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer.
   BJU Int, 100(6): 1254-8. [Abstract] [Full-text]
7. Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading.
   BJU Int, 100(6): 1240-4. [Abstract] [Full-text]
8. Assessing the vesico-urethral anastomosis after radical retropubic prostatectomy: transrectal ultrasonography can replace cystography.
   BJU Int, 100(6): 1268-71. [Abstract] [Full-text]
9. Prostate adenocarcinoma detected after high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation.
   BJU Int, 100(6): 1272-6. [Abstract] [Full-text]
10. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity.
    BJU Int, 100(6): 1317-21. [Abstract] [Full-text]
11. Molecular markers and mortality in prostate cancer.
    BJU Int, 100(6): 1259-63. [Abstract] [Full-text]
12. Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy.
    BJU Int, 100(6): 1249-53. [Abstract] [Full-text]
13. Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer.
    BJU Int, 100(6): 1245-8. [Abstract] [Full-text]
14. The influence of prostate volume on prostate cancer detection using a combined approach of contrast-enhanced ultrasonography-targeted and systematic grey-scale biopsy.
    BJU Int, 100(6): 1264-7. [Abstract] [Full-text]
15. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    J Natl Cancer Inst, 99(21): 1613-22. [Abstract] [Full-text]
16. Mitochondrial regulation of cancer associated nuclear DNA methylation.
    Biochem Biophys Res Commun, 364(3): 656-61. [Abstract] [Full-text]
17. Serum from rats fed red or yellow tomatoes induces Connexin43 expression independently from lycopene in a prostate cancer cell line.
    Biochem Biophys Res Commun, 364(3): 578-82. [Abstract] [Full-text]
18. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.
    J Urol, 178(6): 2521-5. [Abstract] [Full-text]
19. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy.
    J Urol, 178(6): 2385-9; discussion 2389-90. [Abstract] [Full-text]
20. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
    J Urol, 178(6): 2378-83; discussion 2383-4. [Abstract] [Full-text]
21. Biomarkers for prostate cancer detection.
    J Urol, 178(6): 2252-9. [Abstract] [Full-text]
22. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
    J Urol, 178(6): 2348-52; discussion 2352-3. [Abstract] [Full-text]
23. The short-term and long-term effects of radical prostatectomy on lower urinary tract symptoms.
    J Urol, 178(6): 2397-400; discussion 2400-1. [Abstract] [Full-text]
24. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
    J Urol, 178(6): 2372-6; discussion 2377. [Abstract] [Full-text]
25. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
    J Urol, 178(6): 2260-7. [Abstract] [Full-text]
26. Contrast enhanced ultrasound flash replenishment method for directed prostate biopsies.
    J Urol, 178(6): 2354-8. [Abstract] [Full-text]
27. The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
    J Urol, 178(6): 2391-6; discussion 2396. [Abstract] [Full-text]
28. A novel resectoscope for transurethral resection of bladder tumors and the prostate.
    J Urol, 178(6): 2331-6; discussion 2336. [Abstract] [Full-text]
29. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.
    J Urol, 178(6): 2359-64; discussion 2364-5. [Abstract] [Full-text]
30. Phase I/II trial of high intensity focused ultrasound for the treatment of previously untreated localized prostate cancer.
    J Urol, 178(6): 2366-70; discussion 2370-1. [Abstract] [Full-text]
31. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
    Cancer Res, 67(22): 11083-91. [Abstract] [Full-text]
32. PCPH/ENTPD5 expression enhances the invasiveness of human prostate cancer cells by a protein kinase C delta-dependent mechanism.
    Cancer Res, 67(22): 10859-68. [Abstract] [Full-text]
33. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
    Cancer Res, 67(22): 10657-63. [Abstract] [Full-text]
34. Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells.
    Cancer Res, 67(22): 10642-6. [Abstract] [Full-text]
35. Calcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP Diet and Health Study.
    Am J Epidemiol, 166(11): 1270-9. [Abstract] [Full-text]
36. Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study.
    Am J Epidemiol, 166(11): 1259-69. [Abstract] [Full-text]
37. HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.
    Oncogene, 26(52): 7333-45. [Abstract] [Full-text]
38. TRPV6 channel controls prostate cancer cell proliferation via Ca(2+)/NFAT-dependent pathways.
    Oncogene, 26(52): 7380-5. [Abstract] [Full-text]
39. AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells.
    Oncogene, 26(52): 7346-54. [Abstract] [Full-text]
40. Novel potent organoselenium compounds as cytotoxic agents in prostate cancer cells.
    Bioorg Med Chem Lett, 17(24): 6853-9. [Abstract] [Full-text]
41. Photochemically enhanced delivery of a cell-penetrating peptide nucleic acid conjugate targeting human telomerase reverse transcriptase: effects on telomere status and proliferative potential of human prostate cancer cells.
    Cell Prolif, 40(6): 905-20. [Abstract] [Full-text]
42. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
    J Clin Oncol, 25(33): 5313-8. [Abstract] [Full-text]
43. Prostate cancer: MR imaging-guided galvanotherapy--technical development and first clinical results.
    Radiology, 245(3): 895-902. [Abstract] [Full-text]
44. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.
    Biochem Biophys Res Commun, 364(4): 778-82. [Abstract] [Full-text]
45. Decursin suppresses human androgen-independent PC3 prostate cancer cell proliferation by promoting the degradation of beta-catenin.
    Mol Pharmacol, 72(6): 1599-606. [Abstract] [Full-text]
46. Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
    Mol Pharmacol, 72(6): 1586-92. [Abstract] [Full-text]
47. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells.
    Cancer Chemother Pharmacol, 61(2): 231-42. [Abstract] [Full-text]
48. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
    JAMA, 298(19): 2275-80. [Abstract] [Full-text]
49. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer.
    Expert Opin Biol Ther, 7(12): 1893-902. [Abstract] [Full-text]
50. Active surveillance for favorable-risk prostate cancer: who, how and why?
    Nat Clin Pract Oncol, 4(12): 692-8. [Abstract] [Full-text]
51. Assessment of causes of death in a prostate cancer screening trial.
    Int J Cancer, 122(2): 413-7. [Abstract] [Full-text]
52. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest.
    Int J Cancer, 122(2): 444-51. [Abstract] [Full-text]
53. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01.
    J Clin Oncol, 25(34): 5366-73. [Abstract] [Full-text]
54. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer.
    J Clin Oncol, 25(34): 5359-65. [Abstract] [Full-text]
55. Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial.
    BMJ, 335(7630): 1139. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.